Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer

Cancer Genomics and Proteomics

Volumn 8, Issue 1, 2011, Pages 39-48

  Sohma, Itsuro ^a   Fujiwara, Yoshiyuki ^a   Sugita, Yurika ^a   Yoshioka, Akiko ^a   Shirakawa, Mitsuhiro ^a   Moon, Jeong Ho ^a   Takiguchi, Shuji ^a   Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Microarray; NF kappaB; Parthenolide; Peritoneal dissemination

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; PACLITAXEL; PARTHENOLIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; STOMACH CANCER; TUMOR GROWTH;

EID: 79951962599     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Baeuerle PA and Henkel T: Function and activation of NF-kappa B in the immune system. Ann Rev Immunol 12: 141-179, 1994.
2. Grumont RJ, Rourke IJ and Gerondakis S: Rel-dependent induction of A1 transcription is required to protect B-cells from antigen receptor ligation-induced apoptosis. Genes Dev 13: 400-411, 1999.
3. Jones PL, Ping D and Boss JM: Tumor necrosis factor alpha and interleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-beta and NF-kappaB. Mol Cell Biol 17: 6970-6981, 1997. (Pubitemid 27505927)
4. Lee HH, Dadgostar H, Cheng Q, Shu J and Cheng G: NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96: 9136-9141, 1999. (Pubitemid 29374720)
5. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr.: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
6. Wang CY, Guttridge DC, Mayo MW and Baldwin AS Jr.: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induce apoptosis. Mol Cell Biol 19: 5923-5929, 1999. (Pubitemid 29399297)
7. Zong WX, Edelstein LC, Chen C, Bash J and Gelinas C: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 13: 382-387, 1999. (Pubitemid 29108753)
8. Bargou RC, Emmerich F, Kappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dorken B: Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. Clin Invest 100: 2961-2969, 1997. (Pubitemid 28022832)
9. Dong G, Chen Z, Kato and Van Waes C: The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 59: 3495-3504, 1999. (Pubitemid 29334514)
10. Giri DK and Aggarwal BB: Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T-cell lymphoma Hut-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 273: 14008-14014, 1998. (Pubitemid 28268457)
11. Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin AS Jr.: A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12: 968-981, 1998. (Pubitemid 28204604)
12. Shattuck-Brandt RL and Richmond A: Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 57: 3032-3039, 1997. (Pubitemid 27315057)
13. Wang CY, Mayo MW and Baldwin AS Jr.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996. (Pubitemid 26398259)
14. Garcia-Pineres AJ: Cysteine 38 in P65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 276: 39713-39720, 2001.
15. Bork PM, Schmitz ML, Kuhnt M, Escher C and Heinrich M: Sesquiterpenelactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402: 85-90, 1997. (Pubitemid 27056030)
16. Murphy JJ, Heptinstall S and Mitchell JR: Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 2: 189-192, 1988.
17. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Droge W and Schmit ML: Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 273: 1288-1297, 1998. (Pubitemid 28133643)
18. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr., Sledge GW Jr. and Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159-4169, 2000.
19. Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD and Sweene CJ: Restoring chemotherapy and hormone therapy sensitivity by parthenolide in xenograft hormone-refractory prostate cancer model. Prostate 66: 1498-1511, 2006. (Pubitemid 44465816)
20. Fujiwara Y, Doki Y, Taniguchi H, Sohma I, Takiguchi S, Miyata H, Yamasaki M and Monden M: Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives. Gastric Cancer 10: 197-204, 2007.
21. Yu W, Whang I, Suh I, Averbach A, Chang D and Sugarbaker PH: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228: 347-354, 1998. (Pubitemid 30191697)
22. Nakajima T, Nishi M and Kajitani T: Improvement in treatment results of gastric cancer with surgery and chemotherapy: experience of 9,700 cases in the Cancer Institute Hospital, Tokyo. Semin Surg Oncol 7: 365-372, 1991.
23. Shimada K and Ajani JA: Adjuvant therapy for gastric carcinoma patients in the past 15 years: A review of western and oriental trials. Cancer 86: 1657-1668, 1999. (Pubitemid 29513033)
24. Yamagata S, Nakata B and Hirakawa K: Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. Oncol Rep 12: 973-978, 2004.
25. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H and Noguchi Y: A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma. Hepatogastroenterology 50: 2259-2263, 2003.
26. Eguchi T, Fujii M, Wakabayashi K, Aisaki K, Tsuneda Y, Kochi M and Takayama T: Docetaxel plus 5-fluorouracil for terminal gastric cancer patients with peritoneal dissemination. Hepatogastroenterology 50: 1735-1738, 2003. (Pubitemid 37186576)
27. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nkamura K, Yamanaka T, Uchiyama A, Tanaka M and Katano M: Nuclear factor-kappaB p65 (Re1A) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7: 4136-4142, 2001. (Pubitemid 34044638)
28. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, Takaoka M, Murata T, Nobuhisa T, Matsuoka J, Tanaka N and Naomoto Y: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 289: 27-35, 2003. (Pubitemid 36993834)
29. Taniguchi H, Fujiwara Y, Doki Y, Sugita Y, Sohma I, Miyata H, Takiguchi S, Yasuda T, Tomita N, Morisita R and Monden M: Gene therapy using ets-1 transcriptional factor decoy for peritoneal dissemination of gastric cancer. Int J Cancer 121: 1609-1617, 2007. (Pubitemid 47328722)
30. Chou TC and Talalay P: Analysis of combined drags effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
31. Ajani JA: Chemotherapy for gastric carcinoma: new and old options. Oncology 12: 44-47, 1998.
32. Narahara H, Otani T, Iwanaga T, Okajima K, Katsu K, Sowa M, Kobayashi, K, Yasutomi M, Okuno M, Takami M, Ishida T, Yasutake K, Yamamoto H and Taguchi T: A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group. Gan To Kagaku Ryoho 25: 1021-1026, 1998 (in Japanese).
33. Karin M, Cao Y, Greten FR and Li ZW: NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002. (Pubitemid 37328783)
34. Karin M: The beginning of the end: IκB kinase (IKK) and NF-κB activation. J Biol Chem 274: 27339-27342, 1999.
35. Price MA, Rogers AE and Treisman R: Comparative analysis of the ternary complex factor Elk-1, SAP-1a and SAP-2 (ERP/NET). EMBO J 14: 2589-2601, 1995.
36. Bernal-Mizrachi E, Wen W, Srinivasan S, Klenk A Cohen D and Permutt MA: Activation of ELK-1, an Ets transcription factor, by glucose and EGF treatment of insulinoma cells. Am J Physiol Endocrinol Metab 281: 1286-1299, 2001.
37. Curry EA 3rd, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, O'Connell M and Sweeney CJ: Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 22: 299-305, 2004.
38. Ying TH, Hsieh YH, Hsieh YS and Liu JY: Antisense oligonucleotide Elk-1 suppresses the tumorigenicity of human hepatocellular carcinoma cells. Cell Biol Int 32: 210-216, 2007.